2. Academic Validation
  3. Activated ALK signals through the ERK-ETV5-RET pathway to drive neuroblastoma oncogenesis

Activated ALK signals through the ERK-ETV5-RET pathway to drive neuroblastoma oncogenesis

  • Oncogene. 2018 Mar;37(11):1417-1429. doi: 10.1038/s41388-017-0039-5.
Lucille Lopez-Delisle 1,  Cécile Pierre-Eugène 1,  Caroline Louis-Brennetot 1,  Didier Surdez 1,  Virginie Raynal 1 2,  Sylvain Baulande 2,  Valentina Boeva 3 4,  Sandrine Grossetête-Lalami 1,  Valérie Combaret 5,  Michel Peuchmaur 6 7,  Olivier Delattre 1 8,  Isabelle Janoueix-Lerosey 9 10
Affiliations

Affiliations

  • 1 Institut Curie, PSL Research University, Inserm U830, Equipe Labellisée Ligue contre le Cancer, Paris, France.
  • 2 Institut Curie Genomics of Excellence (ICGex) Platform, Institut Curie Research Center, Paris, France.
  • 3 Institut Cochin, Inserm U1016, CNRS UMR 8104, University Paris Descartes UMR-S1016, Paris, France.
  • 4 Institut Curie, PSL Research University, Inserm U900, Mines ParisTech, Paris, France.
  • 5 Centre Léon Bérard, Laboratoire de Recherche Translationnelle, Lyon, France.
  • 6 Departement of Pathology, AP-HP, Hôpital Universitaire Robert Debré, Paris, France.
  • 7 Université Diderot Paris 7, Paris Sorbonne Cité, Paris, France.
  • 8 SIREDO: Care, Innovation and Research for Children, Adolescents and Young Adults with Cancer, Institut Curie, Paris, France.
  • 9 Institut Curie, PSL Research University, Inserm U830, Equipe Labellisée Ligue contre le Cancer, Paris, France. janoueix@curie.fr.
  • 10 SIREDO: Care, Innovation and Research for Children, Adolescents and Young Adults with Cancer, Institut Curie, Paris, France. janoueix@curie.fr.
PMID: 29321660 DOI: 10.1038/s41388-017-0039-5
Abstract

Activating mutations of the ALK receptor occur in a subset of neuroblastoma tumors. We previously demonstrated that Alk mutations cooperate with MYCN overexpression to induce neuroblastoma in mice and identified RET as being strongly upregulated in MYCN/Alkmut tumors. By a genetic approach in vivo, we now document an oncogenic cooperation between activated RET and MYCN overexpression in neuroblastoma formation. We show that MYCN/RETM919T tumors exhibit histological features and expression profiles close to MYCN/Alkmut tumors. We show that RET transcript levels decrease precedes RET protein levels decrease upon ALK inhibition in neuroblastoma cell lines. Etv5 was identified as a candidate transcription factor regulating RET expression from murine MYCN/Alkmut tumor transcriptomic data. We demonstrate that ETV5 is regulated both at the protein and mRNA levels upon ALK activation or inhibition in neuroblastoma cell lines and that this regulation precedes RET modulation. We document that ALK activation induces ETV5 protein upregulation through stabilization in a MEK/ERK-dependent manner. We show that RNAi-mediated inhibition of ETV5 decreases RET expression. Reporter assays indicate that ETV5 is able to drive RET gene transcription. ChIP-seq analysis confirmed ETV5 binding on the RET promoter and identified an enhancer upstream of the promoter. Finally, we demonstrate that combining RET and ALK inhibitors reduces tumor growth more efficiently than each single agent in MYCN and AlkF1178L-driven murine neuroblastoma. Altogether, these results define the ERK-ETV5-RET pathway as a critical axis driving neuroblastoma oncogenesis downstream of activated ALK.

Figures
Products